Ligand Pharmaceuticals has announced that its partner, Travere Therapeutics, has received FDA approval for FILSPARI® (sparsentan), the first and only medication approved for the treatment of focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome. This development expands FILSPARI’s use beyond its established role in treating IgA nephropathy (IgAN), positioning it as a critical therapeutic option for a patient population estimated to exceed 30,000 individuals in the U.S. alone. The approval underscores the drug’s potential to significantly impact clinical outcomes for patients suffering from this rare kidney disorder.

The Phase 3 DUPLEX Study, which is the largest interventional study in FSGS to date, demonstrated that patients treated with FILSPARI experienced a 46% reduction in proteinuria at Week 108 compared to a 30% reduction for those receiving irbesartan, with statistical significance (p=0.0299). Notably, patients without nephrotic syndrome showed even more pronounced benefits, with a 48% reduction in proteinuria and improved estimated glomerular filtration rate (eGFR). FILSPARI’s dual mechanism of action, targeting endothelin A and angiotensin II receptors, is believed to mitigate kidney damage by addressing inflammation and scarring processes that drive FSGS pathology.

This approval not only marks a significant advancement in the therapeutic landscape for FSGS but also has implications for future research and drug development in rare kidney diseases. The efficacy demonstrated in the DUPLEX Study may shift focus towards targeted therapies that address underlying disease mechanisms rather than symptomatic treatment alone. As FILSPARI becomes a cornerstone of treatment for FSGS, it may catalyze further investigations into similar dual-action drugs, potentially accelerating timelines for developing new therapies in the field of nephrology.

Source: globenewswire.com